Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

Inclusion Criteria:

• Adults 18 years of age at the time of screening or >= 40 years and presenting at leastone comorbidity : high blood pressure; a known obesity and/ or a known and treateddiabete.
• SARS-CoV-2 infection confirmed by molecular biology (RT-PCR on a nasopharyngeal ororopharyngeal swab) or by antigen test validated in the country according to nationalguidelines
• A viral syndrome with or without uncomplicated pneumonia, defined as blood oxygensaturation level (SpO2) >=94%.
• Mild Covid-19 symptoms with an onset < 7 days before inclusion.
• Signed written consent from the patient or his/her representative.
• No need an oxygen therapy according to international guidelines (WHO ProgressionScale, grade 2 to 4)
• Accepting and having the ability to be reached by telephone throughout the study.
• Having designated a contact person who can be contacted in case of emergency.
• Accepted to be reached by phone along throughout the study

Exclusion Criteria:

• Blood oxygen saturation level (SpO2) < 94%.
• Known hypersensitivity to investigational products
• Chronic treatment with inhaled corticosteroids (up to 30 days)
• Known history of renal or hepatic failure
• Abnormal physical examination findings:
• respiratory rate < 25 per minute;
• Clinical hypotension with associated signs justifying hospital care
• Feeling unwell for more than 7 days prior to screening.
• End-organ compromise requiring admission to a resuscitation or continuous care unit orshort-term life-threatening comorbidity with life expectancy < 3 months.
• For any new antiviral included in the study, prior treatment with the antiviral,presence of contraindication to its use or intake of concomitant medication proscribedwith its use.
• Patients with known suicidal thoughts, severe psychiatric disorders or majordepression that is uncontrolled or controlled by one of the prohibited drugs
• Known history of long QT syndrome or severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with recovered ventricular fibrillation)
• Unwilling or unable to comply with the requirements of the study protocol at any timeduring the study, e.g. no access to or not comfortable with use of a smartphone orwith answering questions using a telephone, in the opinion of the Investigator orcannot use an inhalation chamber.
• Any other reason that makes it impossible to monitor the patient during the study.
• Enrolled in other clinical trials with unregistered drugs or with registered drugsthat may interact with any of the study IPs or are contraindicated as concomitanttherapy within the last 3 months prior to screening